Abigail Ferry practices in the division of advanced heart failure and cardiac transplant at Allegheny General Hospital in Pittsburgh, Pa. The author has disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2022 Sep 1;35(9):51-53. doi: 10.1097/01.JAA.0000840504.15807.70.
The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.
美国疾病控制与预防中心估计，每年与心力衰竭相关的国家成本超过 300 亿美元。临床医生和研究人员继续积极寻求降低 650 万受这种疾病影响的成年人发病率和死亡率的措施。达格列净最近成为一种有前途的 FDA 批准的治疗收缩性心力衰竭（更常称为射血分数降低的心力衰竭）患者的疗法。
